Skip to content
DataLookout
Menu

NCT06635746

Dose Escalation Study of Vinpocetine in Healthy Volunteers

StatusRecruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved at least 6 months later, primary endpoint(s) modified, and 1 more.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Jun 1, 2026 to Dec 31, 2026 Show 8 more changesShow less
    • Primary endpoint(s) modified
    • Start date changed from estimate of Jun 1, 2025 to Oct 1, 2025
    • Eligibility criteria expanded, about 10 words
    • Trial status changed: Unknown → Recruiting
    • Enrollment reduced: 20 → 16 participants
    • Trial arms changed: 1 → 2
    • Study sites: 0 to 1
    • Secondary endpoints expanded, about 2 words
  2. Minor Changed Registry marked status Unknown; last known: Not Yet Recruiting
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Treatment-Related Adverse Events to determine maximum tolerated single dose and associated concentrations of vinpocetine at different doses.
Timeframe: Approximately weekly treatments across ~4-6 visits per participant from enrollment until 2 weeks post each treatment.

Secondary (1)

Vinpocentine Concentrations

Arms and interventions

VinpocetineExperimental

Participants will take increasing, single doses of vinpocetine to determine maximum tolerated dose (MTD) based on intolerable side effects. 10 healthy volunteers enrolled, consented and screened; 4 patients failed screening; 6 subjects have taken study drug as single ascending doses. At 350mg dose, 6 subjects tested - 1/6 with intolerable side effect (vomiting). At 400mg dose, 2 subjects had marked nausea. Maxium Tolerated Dose = 350mg single dose. Six subjects to be enrolled in the TID dosing study.

Pharmacokinetics for TID dosing.Experimental

After completion of single dose MTD study, 6 healthy volunteers will receive TID doses to determine PK of TID dosing using blood concentrations.

Drugs: Vinpocetine

Sites

1 site in 1 country

  • Stanford UniversityPalo Alto, California, United States